Revenue and Profit Growth - Total revenue for 2025 is expected to be RMB 852.91 million, an increase of 41.24% compared to RMB 603.89 million in the previous year[3] - Operating profit is projected to reach RMB 266.19 million, reflecting a significant increase of 96.66% from RMB 135.36 million year-on-year[3] - Net profit attributable to shareholders is anticipated to be RMB 235.31 million, up 92.61% from RMB 122.17 million in the same period last year[3] - Net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be RMB 201.22 million, a remarkable increase of 129.65% compared to RMB 87.62 million in the previous year[3] - Basic earnings per share are projected to be RMB 0.37, an increase of 85.00% from RMB 0.20 year-on-year[3] Assets and Equity - Total assets as of the end of the reporting period are expected to be RMB 4,401.61 million, a growth of 19.95% from RMB 3,669.59 million at the beginning of the period[4] - Equity attributable to shareholders is projected to be RMB 3,056.25 million, an increase of 8.79% from RMB 2,809.37 million at the beginning of the period[4] - The weighted average return on equity is expected to rise to 7.74%, an increase of 2.91 percentage points from 4.83% in the previous year[4] Market and Operational Factors - The increase in revenue and profit is primarily driven by rising demand in the domestic special integrated circuit industry and the undertaking of multiple national key research projects[8] - The company has made appropriate provisions for impairment of accounts receivable, notes receivable, and inventory, which has impacted profit-related indicators[7]

Financial Performance - Total operating revenue for 2025 reached RMB 2,843,113.85 million, a year-on-year increase of 39.45%[4] - Operating profit amounted to RMB 443,363.85 million, reflecting a significant growth of 113.93% compared to the previous year[4] - Net profit attributable to shareholders was RMB 333,399.01 million, representing a 91.76% increase year-on-year[4] - The basic earnings per share rose to RMB 1.39, an increase of 87.84% from the previous year[4] - The weighted average return on equity improved to 21.25%, up by 9.08 percentage points compared to the prior year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 3,276,956.48 million, an 18.54% increase from the beginning of the period[4] - The equity attributable to shareholders increased to RMB 1,672,353.74 million, a rise of 12.20%[4] Market Strategy and Revenue Drivers - The company focused on high-end market expansion and increased R&D investment, leading to a higher proportion of high-value-added products[6] - The increase in revenue was driven by higher sales volume and prices of copper-clad laminates, along with optimized product structure[6] Financial Data Disclaimer - The company warns that the financial data is preliminary and subject to change upon the release of the official 2025 annual report[8]

Financial Performance - Total revenue for 2025 was CNY 563.81 million, a decrease of 23.47% compared to the previous year[3] - Operating profit was CNY -183.16 million, and total profit was CNY -183.57 million, indicating a loss[3] - Net profit attributable to shareholders was CNY -146.21 million, with a net profit excluding non-recurring gains and losses of CNY -149.76 million[3] - Total assets at the end of the reporting period were CNY 1,462.87 million, a decrease of 17.99% from the beginning of the period[4] - Shareholders' equity attributable to the parent company was CNY 987.79 million, down 11.94% from the beginning of the period[4] Strategic Direction - The company is undergoing a strategic adjustment, focusing on core business areas, which has led to a temporary decline in revenue[5] - The decline in revenue is attributed to the transition from a visual network security innovator to an AI security computing ecosystem builder[6] - The company is collaborating with domestic chip manufacturers to develop compliant computing solutions[6] Industry Positioning - The AI computing industry is rapidly developing, and the company is positioning itself as a core component supplier in this sector[6] Investor Advisory - Investors are advised to be cautious as the financial data presented is preliminary and unaudited, which may differ from the final annual report[7]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以公司2025年年度的定期报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 1,043,768,680.27 | 805,857,022.19 | 29.52 | | 营业利润 | 301,753,694.59 | 130,714,693.96 | 130.85 | | 利润总额 | 301,220,328.25 | 131,599,169.07 | 128.89 | | 归属于母公司所有者 的净利润 | 272,124,670.05 | 124,988,009.59 | 117.72 | | 归属于母公司所有者 的扣除非经常性损益 | 255,107,825.37 | 94,536,002.40 | 1 ...

Financial Performance - The company achieved total operating revenue of 230.03 million yuan, a year-on-year increase of 13.14%[4] - Net profit attributable to shareholders of the parent company reached 28.94 million yuan, up 26.72% year-on-year[4] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was 23.07 million yuan, reflecting a significant increase of 47.91%[4] - Basic earnings per share were 0.43 yuan, representing a growth of 26.47% compared to the previous year[4] Assets and Equity - The company's total assets at the end of the reporting period were 580.15 million yuan, an increase of 3.41% from the beginning of the period[6] - Shareholders' equity attributable to the parent company was 514.43 million yuan, up 3.75% from the beginning of the period[5] Revenue Drivers - The increase in revenue was primarily driven by strong sales of reproductive tract secretion analyzers and related reagents, as well as the blood analysis production line launched in 2024[6] Cost Management - The company implemented cost control measures that resulted in a decrease in the main product costs, contributing to the higher net profit growth rate compared to revenue growth[6] Return on Assets - The weighted average return on net assets increased by 1.10 percentage points to 5.72%[4] Reporting Accuracy - There are no significant uncertainties affecting the accuracy of the performance report as of the announcement date[9]

Financial Performance - Total revenue for 2025 was RMB 284.51 million, a decrease of 23.89% compared to the previous year[3] - Net profit attributable to shareholders of the parent company reached RMB 9.67 million, an increase of 280.86% year-on-year[3] - Basic earnings per share rose to RMB 0.06, a 200% increase compared to the previous year[3] - The company adjusted its profit forecast, expecting a net profit of RMB 8.4 million to RMB 10 million for 2025, an increase of 230.85% to 293.87% year-on-year[8] Assets and Equity - Total assets at the end of 2025 were RMB 894.93 million, a decrease of 1.73% from the beginning of the year[6] - Equity attributable to shareholders of the parent company increased by 1.98% to RMB 497.43 million[6] Cash Management - The company reversed bad debt provisions of approximately RMB 40 million, significantly improving cash collection efficiency[6] Return on Investment - The weighted average return on net assets increased by 1.44 percentage points to 1.96%[3] Management and Forecasting - The company aims to strengthen management to ensure the accuracy of future performance forecasts[9] - There are no significant uncertainties affecting the accuracy of the performance report[10]

Financial Performance - Total operating revenue for 2025 reached RMB 704.16 million, a year-on-year increase of 19.58%[4] - Operating profit increased to RMB 30.86 million, reflecting a growth of 44.80% compared to the previous year[4] - Total profit rose to RMB 31.89 million, marking a 43.00% increase year-on-year[4] - Net profit attributable to shareholders of the parent company was RMB 22.23 million, up 7.10% from the previous year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased to RMB 9.88 million, a decline of 11.64%[4] - Basic earnings per share increased to RMB 0.0548, representing a growth of 7.03%[4] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 2,019.99 million, an increase of 11.78% from the beginning of the period[4] - Shareholders' equity attributable to the parent company decreased to RMB 903.68 million, down 2.27% from the beginning of the period[4] Market and Sales - The company strengthened market promotion, leading to stable growth in sales of tetanus vaccines[6] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the 2025 annual report[7]

注：1、本报告期初数同法定披露的上年年末数。 证券代码：688176 证券简称：亚虹医药 公告编号：2026-005 江苏亚虹医药科技股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以江苏亚虹医药科技股份有限公司（以下简称"公司"）2025 年年 度报告为准，提请投资者注意投资风险。 | | | | 单位：人民币万元 | | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | 增减变动幅度（%） | | 营业总收入 | 27,712.15 | 20,156.24 | 37.49 | | 营业利润 | -43,130.08 | -38,380.59 | 不适用 | | 利润总额 | -43,636.32 | -38,679.58 | 不适用 | | 归属于母公司所有者的净利润 | -41,934.08 | -38,406.34 | 不适用 | | 归属于母公司所 ...

Financial Performance - The total operating revenue for 2025 reached RMB 659.29 million, an increase of 20.32% compared to the previous year[3] - Operating profit decreased to RMB 94.82 million, down 14.62% year-on-year[3] - Net profit attributable to shareholders of the parent company was RMB 102.63 million, reflecting a growth of 5.89% year-on-year[3] - The basic earnings per share increased to RMB 0.26, a rise of 4.35% compared to the previous year[3] Assets and Equity - Total assets at the end of 2025 amounted to RMB 3,954.47 million, a significant increase of 49.49% from the beginning of the period[5] - Equity attributable to shareholders of the parent company rose to RMB 2,509.11 million, up 67.18% from the beginning of the period[4] - The net asset per share attributable to shareholders of the parent company increased to RMB 5.58, a growth of 42.10% from the beginning of the period[4] Market and Product Impact - The decline in operating profit and total profit was influenced by the termination of some product collaborations, despite a significant increase in self-produced product revenue[6] - The rapid development of new-generation information technology industries, such as artificial intelligence, has driven demand for advanced chip products, positively impacting the company's core product sales[6] Initial Public Offering - The company completed its initial public offering on November 18, 2025, raising a total of RMB 1,010.30 million, significantly boosting its asset and equity scale[7]

Financial Performance Forecast - The company expects a net profit attributable to shareholders of approximately 70 million to 85 million yuan for Q1 2026, an increase of 44.564 million to 59.564 million yuan compared to the same period last year, representing a year-on-year increase of 175.20% to 234.17%[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be around 53 million to 65 million yuan, an increase of 39.6998 million to 51.6998 million yuan compared to the same period last year, reflecting a year-on-year increase of 298.49% to 388.71%[3] - The total profit for the same period last year was 25.4563 million yuan, with a net profit attributable to shareholders of 25.436 million yuan and a net profit after deducting non-recurring gains and losses of 13.3002 million yuan[5] Factors Influencing Profit - The increase in net profit is primarily due to the sustained competitive advantage in the evaporation source equipment sector, leading to significant revenue growth in equipment-related businesses[8] Earnings Forecast and Risks - The earnings forecast has not been audited by registered accountants and is based on preliminary calculations by the company's financial department[4] - The company has not identified any significant uncertainties that could affect the accuracy of this earnings forecast[9] - Investors are advised to pay attention to investment risks as the forecast data is preliminary and the accurate financial data will be disclosed in the official Q1 2026 report[10]